WordNet

characterized by or caused by allergy; "an allergic reaction"
having an allergy or peculiar or excessive susceptibility (especially to a specific factor); "allergic children"; "hypersensitive to pollen" (同)hypersensitive, hypersensitized, hypersensitised, sensitized, sensitised, supersensitive, supersensitized, supersensitised
inflammation of one of the paranasal sinuses

PrepTutorEJDIC

アレルギー性の;(…に)アレルギーを起こす《+『to』+『名』》 / 《補語にのみ用いて》《話》(…に)神経過敏の,(…が)大きらいの《+『to』+『名』(do『ing)』》
洞炎,(特に)静脈洞炎

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. Chronic rhinosinusitis: Management
2. Allergic fungal rhinosinusitis
3. アレルギー性鼻炎：臨床症状、疫学、および診断 allergic rhinitis clinical manifestations epidemiology and diagnosis
4. アレルギー性鼻炎の薬物療法 pharmacotherapy of allergic rhinitis
5. 慢性副鼻腔炎：臨床症状、病態生理、および診断 chronic rhinosinusitis clinical manifestations pathophysiology and diagnosis

English Journal

Medial maxillectomy in recalcitrant sinusitis: when, why and how?

Konstantinidis I, Constantinidis J.Author information 2nd Academic ORL Department, Aristotle University, Papageorgiou Hospital, Thessaloniki, Greece.AbstractPURPOSE OF REVIEW: We reviewed all journal articles relevant to endoscopic medial maxillectomy in patients with recalcitrant chronic maxillary sinusitis in order to present all indications, the underlying pathophysiology and the developed surgical techniques.
Current opinion in otolaryngology & head and neck surgery.Curr Opin Otolaryngol Head Neck Surg.2014 Feb;22(1):68-74. doi: 10.1097/MOO.0000000000000009.
PURPOSE OF REVIEW: We reviewed all journal articles relevant to endoscopic medial maxillectomy in patients with recalcitrant chronic maxillary sinusitis in order to present all indications, the underlying pathophysiology and the developed surgical techniques.RECENT FINDINGS: Despite the high success
PMID 24231413

The association between allergy and chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations.

Wilson KF, McMains KC, Orlandi RR.Author information Division of Otolaryngology-Head and Neck Surgery, University of Utah, Salt Lake City, UT.AbstractBACKGROUND: The relationship between allergy and chronic rhinosinusitis (CRS) remains ill-defined and controversial. The association between the 2 is unclear, making an evidence-based decision of whether to evaluate and treat allergies in CRS patients difficult. The purposes of this systematic review are to (1) examine the relationship between allergy and CRS without nasal polyps (CRSsNP), (2) examine the same for allergy and CRS with nasal polyps (CRSwNP), and (3) recommend evaluation and treatment based on the evidence.
International forum of allergy & rhinology.Int Forum Allergy Rhinol.2014 Jan 2. doi: 10.1002/alr.21258. [Epub ahead of print]
BACKGROUND: The relationship between allergy and chronic rhinosinusitis (CRS) remains ill-defined and controversial. The association between the 2 is unclear, making an evidence-based decision of whether to evaluate and treat allergies in CRS patients difficult. The purposes of this systematic revie
PMID 24395734

Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.

Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G.Author information Houston Allergy & Asthma Associates , Baytown, TX , USA.AbstractAbstract Background: Omalizumab, a humanised anti-immunoglobulin E monoclonal antibody for treatment of uncontrolled moderate-to-severe or severe persistent allergic asthma, was developed as a lyophilised powder for reconstitution. A liquid formulation in pre-filled syringes has now been developed. The purpose of this study was to assess the immunogenicity and safety of this liquid formulation. Methods: In this multinational, open-label, single-arm study, patients (≥12 years) with moderate-to-severe allergic asthma were treated for 24 weeks with the liquid formulation of omalizumab (75 or 150 mg in a pre-filled syringe) at 2 or 4 week intervals. Immunogenicity was assessed by measurement of human anti-therapeutic antibody (ATA) levels. Safety was assessed by monitoring adverse events (AEs), haematology, blood chemistry, urine analysis and vital signs. Results: A total of 155 patients were enrolled in the study. No patient had a confirmed positive ATA test result. Most frequent individual AEs were asthma (17.4%), sinusitis (17.4%) and upper respiratory tract infection (11.6%). Fourteen patients (9.0%) had serious AEs and there was one death (not treatment related). There were no cases of anaphylaxis according to Sampson criteria. Most patients remained within normal ranges for haematology and biochemistry laboratory variables. Conclusions: Omalizumab in pre-filled syringes was not associated with immunogenicity. This novel formulation, which does not require reconstitution, had a safety profile consistent with the lyophilised formulation. A limitation of this study is that efficacy of omalizumab in the treatment of asthma was not specifically addressed herein. Clinicaltrials.gov identifier: NCT00500539.
Current medical research and opinion.Curr Med Res Opin.2014 Jan;30(1):59-66. doi: 10.1185/03007995.2013.844115. Epub 2013 Oct 1.
Abstract Background: Omalizumab, a humanised anti-immunoglobulin E monoclonal antibody for treatment of uncontrolled moderate-to-severe or severe persistent allergic asthma, was developed as a lyophilised powder for reconstitution. A liquid formulation in pre-filled syringes has now been developed.
PMID 24028677

Japanese Journal

免疫(5)アレルギー疾患と免疫異常 2. アレルギー性鼻炎、副鼻腔炎、気管支喘息

東京女子医科大学雑誌 85(5), 151-156, 2015-10-25
NAID 110009976051

Safety and efficacy of fluticasone furoate nasal spray in Japanese children 2 to <15 years of age with perennial allergic rhinitis: A multicentre, open-label trial